The histone methyltransferase EZH2 has been in the limelight of the field of 
cancer epigenetics for a decade now since it was first discovered to exhibit an 
elevated expression in metastatic prostate cancer. It persists to attract much 
scientific attention due to its important role in the process of cancer 
development and its potential of being an effective therapeutic target. Thus 
here we review the dysregulation of EZH2 in prostate cancer, its function, 
upstream regulators, downstream effectors, and current status of EZH2-targeting 
approaches. This review therefore provides a comprehensive overview of EZH2 in 
the context of prostate cancer.